Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
Kelloff
Gary J
GJ
Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA. kelloffg@mail.nih.gov
Coffey
Donald S
DS
Chabner
Bruce A
BA
Dicker
Adam P
AP
Guyton
Kathryn Z
KZ
Nisen
Perry D
PD
Soule
Howard R
HR
D'Amico
Anthony V
AV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D015195:Drug Design; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000096:biosynthesis*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen